arrow
A

Andrea Spallanzani

University Hospital of Modena
H指数:26
被引数:2,504

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real world outcomes of perioperative FLOT in an Italian cohort of resectable gastric cancer: long term follow-up of prospective observational Real-FLOT study

可切除胃癌意大利队列中围手术期FLOT的长期随访真实世界结果:前瞻性观察性Real-FLOT研究

2026-09-170
OAAI
Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma☆

KEYNOTE-585研究中生存的替代终点:新辅助/辅助性帕博利珠单抗联合化疗对比安慰剂联合化疗治疗胃或胃食管结合部腺癌☆

2026-02-260
OAAI
Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: a secondary endpoint of the ARMANI phase 3 trial

帕克他赛和雷莫芦单抗序贯维持治疗在晚期胃肠癌中的患者报告结局:ARMANI III期试验的次要终点

2025-10-200
PRE
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial
2025-04-080
OAAI
Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI survey

意大利医学肿瘤学会(AIOM)加里波第调查中转移性队列的生存分析

2024-11-010
OAAI
Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic
2024-11-012
OA
Pattern of expression, transcriptional states and clinical implications of tumour-infiltrating lymphocytes (TILs) in curatively-treated cholangiocarcinoma (CCA) patients (pts): The TILBIL study

表达模式、转录状态及肿瘤浸润淋巴细胞(TILs)在治愈性治疗的胆管癌(CCA)患者(pts)中的临床意义:TILBIL研究

2024-09-010
PRE
Isolated LUng Metastases in pancreatic AdenoCArcinoma patients in a multicenter Italian cohort: The LUMACA study

孤立性肺转移瘤在胰腺腺癌患者中的多中心意大利队列研究:LUMACA研究

2024-09-010
PRE
Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma
2024-08-010
OAAI
Hepatectomy v°ersus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study
2024-07-250
PRE
Current trends in the management of Gastro-oEsophageal cancers: Updates to the ESSO core curriculum (ESSO-ETC-UGI-WG initiative)
EJSO
IF2.9
2024-07-011
PRE
Adjuvant trastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: The TRINITY trial
2024-06-011
PRE
Switch maintenance with ramucirumab plus paclitaxel versus continuation of oxaliplatin-based chemotherapy in advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: Final results and key biomarkers of the ARMANI phase III trial
2024-06-010
PRE
Association of hypothyroidism with survival in pancreatic cancer: retrospective cohort study
2024-01-091
OAAI